SCN5A gene
Showing 1 - 25 of >10,000
People Who Have Genetic Changes and Features of Autism: Simons
Recruiting
- 16P11.2 Deletion Syndrome
- +184 more
-
New York, New York
- +1 more
Jan 6, 2023
Dravet Syndrome Trial in Melbourne (ETX101)
Not yet recruiting
- Dravet Syndrome
-
Melbourne, AustraliaThe Royal Children's Hospital
Oct 30, 2023
Stratification of Overlap Syndrome Phenotype in E1784K Mutation
Recruiting
- Long QT Syndrome
- +3 more
-
Saint-Pierre, France, RéunionCHU de La Réunion
Oct 19, 2022
SCN2A Encephalopathy, SCN8A Encephalopathy Trial in Tacoma (Part A: 0.5mg/kg/day PRAX-562 for 16 Weeks, Part A: 0.5mg/kg/day
Recruiting
- SCN2A Encephalopathy
- SCN8A Encephalopathy
- Part A: 0.5mg/kg/day PRAX-562 for 16 Weeks
- +2 more
-
Tacoma, WashingtonPraxis Research Site
Apr 18, 2023
Fibronectin Type ? Domain Containing Protein 5 \ Irsin Gene
Recruiting
- Hepatitis B, Chronic
- genotyping
-
Sohag, EgyptSohag university Hospital
Sep 4, 2023
LGMD2C Trial (ATA-200)
Not yet recruiting
- LGMD2C
- ATA-200
- (no location specified)
Aug 1, 2023
Hemophilia B Trial (CSL222 (AAV5-hFIXco-Padua))
Not yet recruiting
- Hemophilia B
- CSL222 (AAV5-hFIXco-Padua)
- (no location specified)
Aug 14, 2023
LCA5 Trial (AAV8.hLCA5)
Not yet recruiting
- LCA5
- AAV8.hLCA5
- (no location specified)
Nov 22, 2022
Clinical Significance and Coexistence of Polymorphisms of
Active, not recruiting
- Ligament; Laxity
- Recurrent Patellar Dislocation
- genetic test
- Beighton joint laxity test
-
Lodz, Lodzkie Voivodeship, Poland
- +1 more
Feb 28, 2023
Neuronal Ceroid Lipofuscinosis CLN5 Trial in Rochester (NGN-101)
Recruiting
- Neuronal Ceroid Lipofuscinosis CLN5
- NGN-101
-
Rochester, New York
- +1 more
Jan 19, 2023
Hemophilia A, Gene Therapy, Clotting Disorders Trial in Johannesburg, London, Southampton (Valoctocogene Roxaparvovec)
Recruiting
- Hemophilia A
- +3 more
- Valoctocogene Roxaparvovec
-
Seoul, Korea, Republic of
- +8 more
Jan 6, 2023
Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy
Recruiting
- Epilepsy
-
Boston, Massachusetts
- +3 more
Oct 11, 2023
Mucopolysaccharidosis Type II (MPS II) Trial in Oakland, Montréal (RGX-121)
Recruiting
- Mucopolysaccharidosis Type II (MPS II)
- RGX-121
-
Oakland, California
- +1 more
Oct 6, 2022
Spastic Paraplegia Type 50 Trial in Toronto (MELPIDA)
Active, not recruiting
- Spastic Paraplegia Type 50
- MELPIDA
-
Toronto, Ontario, CanadaThe Hospital for Sick Children
Oct 5, 2023
Multiple Myeloma Trial in Wuhan (Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells)
Recruiting
- Multiple Myeloma
- Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells
-
Wuhan, Hubei, ChinaUnion Hospital, Tongji Medical College, Huazhong University of S
Aug 11, 2023
Na+ Channel mRNA Regulation in Heart Failure
Completed
- Heart Failure
- no intervention is involved
- (no location specified)
Feb 28, 2022
Osteoarthritis, Knee, Osteo Arthritis Knee, Knee Osteoarthritis Trial (GNSC-001, transient immune-modulation, Placebo)
Not yet recruiting
- Osteoarthritis, Knee
- +9 more
- GNSC-001
- +2 more
- (no location specified)
Apr 19, 2023
Solid Tumors Trial in Toronto (Afatinib)
Active, not recruiting
- Solid Tumors
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
May 12, 2022
Enteric Fever, Acute Febrile Illness, Typhoid Trial in Vellore (5-gene transcription signature)
Recruiting
- Enteric Fever
- +4 more
- 5-gene transcription signature
-
Vellore, IndiaChristian Medical Centre
Jun 15, 2022
Congenital Adrenal Hyperplasia Trial in United States (AAV BBP-631)
Recruiting
- Congenital Adrenal Hyperplasia
- AAV BBP-631
-
Los Angeles, California
- +6 more
Jul 29, 2022
Hemophilia A Trial in Worldwide (SPK-8011)
Recruiting
- Hemophilia A
- SPK-8011
-
Sacramento, California
- +18 more
Jul 15, 2022
Retinitis Pigmentosa Trial in Nantes (AAV2/5-hPDE6B)
Active, not recruiting
- Retinitis Pigmentosa
- AAV2/5-hPDE6B
-
Nantes, FranceClinique Ophtalmologique, CHU de Nantes
Feb 28, 2022
Hereditary Angioedema, HAE Trial in United States (Dose 1 of BMN 331, Dose 2 of BMN 331, Dose 3 of BMN 331)
Recruiting
- Hereditary Angioedema
- HAE
- Dose 1 of BMN 331
- +4 more
-
Birmingham, Alabama
- +11 more
Jan 26, 2023